Combined Vildagliptin and Metformin Exert Better Cardioprotection than Monotherapy against Ischemia-Reperfusion Injury in Obese-Insulin Resistant Rats

摘要: Background Obese-insulin resistance caused by long-term high-fat diet (HFD) consumption is associated with left ventricular (LV) dysfunction and increased risk of myocardial infarction. Metformin vildagliptin have been shown to exert cardioprotective effects. However, the effect these drugs on hearts under obese-insulin ischemia-reperfusion (I/R) injury unclear. We hypothesized that combined metformin provide better protective effects against I/R than monotherapy in resistant rats. Methodology Male Wistar rats were fed either HFD or normal diet. Rats each group divided into 4 subgroups receive vildagliptin, metformin, saline for 21 days. Ischemia due anterior descending artery ligation was allowed 30-min, followed 120-min reperfusion. Metabolic parameters, heart rate variability (HRV), LV function, infarct size, mitochondrial calcium transient, Bax Bcl-2, Connexin 43 (Cx43) determined. developed insulin after 12 weeks consumption. Vildagliptin, improved metabolic HRV, function. During I/R, all treatments reduced size Bax, function rats. only delayed time first VT/VF onset, arrhythmia score mortality rate, p-Cx43 rats. Conclusion Although both attenuate provided outcomes single therapy reducing rate.